Fenwick & West represented LifeSprout Inc., a privately held company developing revolutionary products for aesthetic and regenerative medicine, in its $28.5 million Series A financing. The financing was led by Redmile Group, LLC, along with additional new investors Nexus Management, LP; Emerald Development Managers, LP; and the Abell Foundation.

LifeSprout is using proceeds to support clinical development of novel therapeutic products from its Regenerative Matrix platform. More information about the financing can be obtained from LifeSprout’s announcement​.

The Fenwick transaction team included corporate partner Ian Goldstein and associates Feihong Xu, Kristin Esannason and Jennifer Wu.

Login

Don’t have an account yet?

Register